HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...